Skip to main content
PMC home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1996 Nov 1;184(5):1601–1608. doi: 10.1084/jem.184.5.1601

Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia

PMCID: PMC2192853  PMID: 8920850

Abstract

High-density lipoprotein (HDL) has been found to neutralize LPS activity in vitro and in animals in vivo. We sought to determine the effects of reconstituted HDL (rHDL) on LPS responsiveness in humans in a double-blind, randomized, placebo-controlled, cross-over study. rHDL, given as a 4-h infusion at 40 mg/kg starting 3.5 h before endotoxin challenge (4 ng/kg), reduced flu-like symptoms during endotoxemia, but did not influence the febrile response. rHDL potently reduced the endotoxin-induced release of TNF, IL-6, and IL-8, while only modestly attenuating the secretion of proinflammatory cytokine inhibitors IL- 1ra, soluble TNF receptors and IL-10. In addition, rHDL attenuated LPS- induced changes in leukocyte counts and the enhanced expression of CD11b/CD18 on granulocytes. Importantly, rHDL infusion per se, before LPS administration, was associated with a downregulation of CD14, the main LPS receptor, on monocytes. This effect was biologically relevant, since monocytes isolated from rHDL-treated whole blood showed reduced expression of CD14 and diminished TNF production upon stimulation with LPS. These results suggest that rHDL may inhibit LPS effects in humans in vivo not only by binding and neutralizing LPS but also by reducing CD14 expression on monocytes.

Full Text

The Full Text of this article is available as a PDF (555.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arfors K. E., Lundberg C., Lindbom L., Lundberg K., Beatty P. G., Harlan J. M. A monoclonal antibody to the membrane glycoprotein complex CD18 inhibits polymorphonuclear leukocyte accumulation and plasma leakage in vivo. Blood. 1987 Jan;69(1):338–340. [PubMed] [Google Scholar]
  2. Baumberger C., Ulevitch R. J., Dayer J. M. Modulation of endotoxic activity of lipopolysaccharide by high-density lipoprotein. Pathobiology. 1991;59(6):378–383. doi: 10.1159/000163681. [DOI] [PubMed] [Google Scholar]
  3. Bazil V., Strominger J. L. Shedding as a mechanism of down-modulation of CD14 on stimulated human monocytes. J Immunol. 1991 Sep 1;147(5):1567–1574. [PubMed] [Google Scholar]
  4. Cué J. I., DiPiro J. T., Brunner L. J., Doran J. E., Blankenship M. E., Mansberger A. R., Hawkins M. L. Reconstituted high density lipoprotein inhibits physiologic and tumor necrosis factor alpha responses to lipopolysaccharide in rabbits. Arch Surg. 1994 Feb;129(2):193–197. doi: 10.1001/archsurg.1994.01420260089012. [DOI] [PubMed] [Google Scholar]
  5. Eggesbø J. B., Hjermann I., Høstmark A. T., Joø G. B., Kierulf P. Lipopolysaccharide-induced monocyte procoagulant activity, fibrinopeptide A, and PAI-I levels in persons with high or low levels of HDL-lipoprotein. Thromb Res. 1993 Apr 15;70(2):161–171. doi: 10.1016/0049-3848(93)90157-j. [DOI] [PubMed] [Google Scholar]
  6. Eichacker P. Q., Farese A., Hoffman W. D., Banks S. M., Mouginis T., Richmond S., Kuo G. C., Macvittie T. J., Natanson C. Leukocyte CD11b/18 antigen-directed monoclonal antibody improves early survival and decreases hypoxemia in dogs challenged with tumor necrosis factor. Am Rev Respir Dis. 1992 May;145(5):1023–1029. doi: 10.1164/ajrccm/145.5.1023. [DOI] [PubMed] [Google Scholar]
  7. Emancipator K., Csako G., Elin R. J. In vitro inactivation of bacterial endotoxin by human lipoproteins and apolipoproteins. Infect Immun. 1992 Feb;60(2):596–601. doi: 10.1128/iai.60.2.596-601.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Feingold K. R., Funk J. L., Moser A. H., Shigenaga J. K., Rapp J. H., Grunfeld C. Role for circulating lipoproteins in protection from endotoxin toxicity. Infect Immun. 1995 May;63(5):2041–2046. doi: 10.1128/iai.63.5.2041-2046.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Flegel W. A., Wölpl A., Männel D. N., Northoff H. Inhibition of endotoxin-induced activation of human monocytes by human lipoproteins. Infect Immun. 1989 Jul;57(7):2237–2245. doi: 10.1128/iai.57.7.2237-2245.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Frey E. A., Miller D. S., Jahr T. G., Sundan A., Bazil V., Espevik T., Finlay B. B., Wright S. D. Soluble CD14 participates in the response of cells to lipopolysaccharide. J Exp Med. 1992 Dec 1;176(6):1665–1671. doi: 10.1084/jem.176.6.1665. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Harris H. W., Grunfeld C., Feingold K. R., Rapp J. H. Human very low density lipoproteins and chylomicrons can protect against endotoxin-induced death in mice. J Clin Invest. 1990 Sep;86(3):696–702. doi: 10.1172/JCI114765. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hubsch A. P., Powell F. S., Lerch P. G., Doran J. E. A reconstituted, apolipoprotein A-I containing lipoprotein reduces tumor necrosis factor release and attenuates shock in endotoxemic rabbits. Circ Shock. 1993 May;40(1):14–23. [PubMed] [Google Scholar]
  13. Lerch P. G., Förtsch V., Hodler G., Bolli R. Production and characterization of a reconstituted high density lipoprotein for therapeutic applications. Vox Sang. 1996;71(3):155–164. doi: 10.1046/j.1423-0410.1996.7130155.x. [DOI] [PubMed] [Google Scholar]
  14. Levine D. M., Parker T. S., Donnelly T. M., Walsh A., Rubin A. L. In vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):12040–12044. doi: 10.1073/pnas.90.24.12040. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Marchant A., Duchow J., Delville J. P., Goldman M. Lipopolysaccharide induces up-regulation of CD14 molecule on monocytes in human whole blood. Eur J Immunol. 1992 Jun;22(6):1663–1665. doi: 10.1002/eji.1830220650. [DOI] [PubMed] [Google Scholar]
  16. Mészáros K., Aberle S., White M., Parent J. B. Immunoreactivity and bioactivity of lipopolysaccharide-binding protein in normal and heat-inactivated sera. Infect Immun. 1995 Jan;63(1):363–365. doi: 10.1128/iai.63.1.363-365.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Parker T. S., Levine D. M., Chang J. C., Laxer J., Coffin C. C., Rubin A. L. Reconstituted high-density lipoprotein neutralizes gram-negative bacterial lipopolysaccharides in human whole blood. Infect Immun. 1995 Jan;63(1):253–258. doi: 10.1128/iai.63.1.253-258.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Quezado Z. M., Natanson C., Banks S. M., Alling D. W., Koev C. A., Danner R. L., Elin R. J., Hosseini J. M., Parker T. S., Levine D. M. Therapeutic trial of reconstituted human high-density lipoprotein in a canine model of gram-negative septic shock. J Pharmacol Exp Ther. 1995 Feb;272(2):604–611. [PubMed] [Google Scholar]
  19. Read T. E., Harris H. W., Grunfeld C., Feingold K. R., Kane J. P., Rapp J. H. The protective effect of serum lipoproteins against bacterial lipopolysaccharide. Eur Heart J. 1993 Dec;14 (Suppl K):125–129. [PubMed] [Google Scholar]
  20. Tobias P. S., Soldau K., Gegner J. A., Mintz D., Ulevitch R. J. Lipopolysaccharide binding protein-mediated complexation of lipopolysaccharide with soluble CD14. J Biol Chem. 1995 May 5;270(18):10482–10488. doi: 10.1074/jbc.270.18.10482. [DOI] [PubMed] [Google Scholar]
  21. Ulevitch R. J., Tobias P. S. Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu Rev Immunol. 1995;13:437–457. doi: 10.1146/annurev.iy.13.040195.002253. [DOI] [PubMed] [Google Scholar]
  22. Wright S. D., Ramos R. A., Hermanowski-Vosatka A., Rockwell P., Detmers P. A. Activation of the adhesive capacity of CR3 on neutrophils by endotoxin: dependence on lipopolysaccharide binding protein and CD14. J Exp Med. 1991 May 1;173(5):1281–1286. doi: 10.1084/jem.173.5.1281. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Wurfel M. M., Hailman E., Wright S. D. Soluble CD14 acts as a shuttle in the neutralization of lipopolysaccharide (LPS) by LPS-binding protein and reconstituted high density lipoprotein. J Exp Med. 1995 May 1;181(5):1743–1754. doi: 10.1084/jem.181.5.1743. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Wurfel M. M., Kunitake S. T., Lichenstein H., Kane J. P., Wright S. D. Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS. J Exp Med. 1994 Sep 1;180(3):1025–1035. doi: 10.1084/jem.180.3.1025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Ziegler-Heitbrock H. W., Ulevitch R. J. CD14: cell surface receptor and differentiation marker. Immunol Today. 1993 Mar;14(3):121–125. doi: 10.1016/0167-5699(93)90212-4. [DOI] [PubMed] [Google Scholar]
  26. van Deventer S. J., Büller H. R., ten Cate J. W., Aarden L. A., Hack C. E., Sturk A. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood. 1990 Dec 15;76(12):2520–2526. [PubMed] [Google Scholar]
  27. von der Möhlen M. A., Kimmings A. N., Wedel N. I., Mevissen M. L., Jansen J., Friedmann N., Lorenz T. J., Nelson B. J., White M. L., Bauer R. Inhibition of endotoxin-induced cytokine release and neutrophil activation in humans by use of recombinant bactericidal/permeability-increasing protein. J Infect Dis. 1995 Jul;172(1):144–151. doi: 10.1093/infdis/172.1.144. [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES